Higher levels of antibodies to the tumour‐associated antigen cyclin B1 in cancer‐free individuals than in patients with breast cancer. (October 2014)

• Record Type: Journal Article
• Authors: Pandey, J. P.; Kistner‐Griffin, E.; Namboodiri, A. M.; Iwasaki, M.; Kasuga, Y.; Hamada, G. S.; Tsugane, S.
• Is Part Of: Clinical and experimental immunology. Volume 178:Number 1(2014:Oct.)
• Page Start: 75
• Page End: 78
• Publication Date: 2014-10
• Subjects: Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.12385
• Languages: English
• ISSNs: 0009-9104

Abstract

<abstract abstract-type="main"> <title>Summary</title> <p>Cyclin B1 is a checkpoint protein that regulates cell division from G2 to the M phase. Studies in mice have shown that cyclin B1 vaccine‐induced immunity significantly delayed or prevented the spontaneous cancer development later in life. We hypothesized that if these results showing a protective effect of anti‐cyclin B1 antibodies could be extrapolated to the human condition, cancer‐free individuals should have higher levels of endogenous antibodies than patients with cancers characterized by the over‐expression of this tumour‐associated antigen. To test this hypothesis, we characterized a large (1739 subjects) number of multi‐ethnic patients with breast cancer (which over‐expresses cyclin B1) and matched controls for anti‐cyclin B1 immunoglobulin (Ig)G antibodies. Multivariate analyses, after adjusting for the covariates, showed that cancer‐free individuals had significantly higher levels of naturally occurring IgG antibodies to cyclin B1 than patients with breast cancer (mean ± standard deviation: 148·0 ± 73·6 <italic>versus</italic> 126·1 ± 67·8 arbitrary units per ml; <italic>P</italic> &lt; 0·0001). These findings may have important implications for cyclin B1‐based immunotherapy against breast cancer and many other cyclin B1‐over‐expressing malignancies.</p> </abstract>